U.S. DOJ Closes Probe Into AstraZeneca's Heart Drug Brilinta

The Wall Street Journal (online registration rquired): LONDON—The U.S. Department of Justice is closing a probe into AstraZeneca PLC's heart drug Brilinta, removing a significant cloud over the U.K. drug maker's outlook, the company said Tuesday.

Brilinta was approved in the U.S. in 2011, but the Justice Department cast doubts over the future of the drug last October when it decided to investigate a clinical trial that demonstrated Brilinta's benefits over a rival treatment

Read article

Share